Investigators surveying the state of T‑cell receptor (TCR) therapy for ovarian cancer report persistent translational challenges despite promising biology. Obstacles include antigen heterogeneity across tumors, the immunosuppressive tumor microenvironment in ovarian malignancies, and on‑target off‑tumor toxicity risk. Researchers call for improved target discovery, combinatorial strategies to remodel the microenvironment, and refined patient selection to advance TCR approaches from preclinical models into durable clinical responses.